A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| Mizoribine | Mizoribine. Group: Biochemicals. Alternative Names: 1-(b-D-Ribofuranosyl)-5-hydroxyimidazole-4-carboxamide. Grades: Highly Purified. CAS No. 50924-49-7. Pack Sizes: 50mg, 100mg, 250mg, 500mg, 1g. Molecular Formula: C9H13N3O6. US Biological Life Sciences. |  Worldwide |
| MIZORIBINE | MIZORIBINE. Uses: Designed for use in research and industrial production. Additional or Alternative Names: N'-[BETA-D-RIBOFURANOSYL]-5-HYDROXYIMIDAZOLE-4-CARBOXAMIDE. Product Category: Heterocyclic Organic Compound. CAS No. 50524-49-7. Molecular formula: C9H13N3O6. Mole weight: 259.22. Purity: 0.96. IUPACName: 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxyimidazole-4-carboxamide. Canonical SMILES: C1=NC(=C(N1C2C(C(C(O2)CO)O)O)O)C(=O)N. Density: 2.06g/cm³. Product ID: ACM50524497. Alfa Chemistry ISO 9001:2015 Certified. |  |
| Mizoribine 5-monophosphate | Mizoribine 5-monophosphate is a widely utilized pharmaceutical compound within the biomedical sector, aiding in studying diverse autoimmune disorders, such as rheumatoid arthritand lupus nephritis. CAS No. 62025-48-3. Mole weight: 259.22. |  |
| MJ 15 | MJ 15 is a CB1 receptor antagonist with IC50 value of 118.9 pM for rat CB1 receptors. It can inhibit food intake and increase body weight in diet-induced obese rats and mice. Synonyms: MJ15; MJ 15; MJ-15; 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(3-pyridinylmethyl)-1H-pyrazole-3-carboxamide. Grades: ≥99% by HPLC. CAS No. 944154-76-1. Molecular formula: C23H17Cl3N4O. Mole weight: 471.77. | |
| MJ33 lithium salt | MJ33 is a selective and reversible inhibitor of the acidic, calcium-independent (ai)PLA2 activity of Prdx6. Prdx6 is a bifunctional enzyme with both non-selenium glutathione peroxidase (Gpx) and PLA2 activities. Synonyms: 1-Hexadecyl-3-(trifluoroethyl)-sn-glycero-2-phosphomethanol, Li. Grades: ≥95%. CAS No. 1007476-63-2. Molecular formula: C22H43F3LiO6P. Mole weight: 498.5. | |
| MJ33 lithium salt | powder, ?90% (NMR). Group: Fluorescence/luminescence spectroscopy. |  |
| MJ347-81F4-B | MJ347-81F4-B is originally isolated from Amycolatopsis sp. MJ347-81F4. It has good anti-gram-positive bacteria activity, including clinically isolated methicillin-resistant Staphylococcus aureus (MIC 0.05-0.2 μg/mL). Molecular formula: C60H58N14O18S5. Mole weight: 1423.51. | |
| MJN110 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| MJN110 | MJN110 is a potent and selective monoacylglycerol lipase (MAGL) inhibitor that modulates the synaptic processes. MJN110 has the potential for the treatment of acute nausea and vomiting as well as anticipatory nausea by elevation of endogenous cannabinoid 2-arachidonoylglycerol (2-AG) levels in the brain. Uses: Antihyperalgesic agent. Synonyms: MJN-110; MJN 110; MJN110;2,5-dioxopyrrolidin-1-yl 4-(bis(4-chlorophenyl)methyl)piperazine-1-carboxylate. Grades: 98%. CAS No. 1438416-21-7. Molecular formula: C22H21Cl2N3O4. Mole weight: 462.33. | |
| MJN110 | MJN110 is an orally active and selective monoacylglycerol lipase (MAGL) inhibitor with IC50s of 9.1 nM and 2.1 nM for hMAGL and 2-arachidonoylglycerol (2-AG), respectively[1]. MJN110 produces opioid-sparing effects and displays strong antihyperalgesic activity[2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1438416-21-7. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-117474. |  |
| MJN228 | MJN228 is a lipid-binding protein nucleobindin-1 ( NUCB1 ) inhibitor with an IC 50 of 3.3 μM [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 459168-97-9. Pack Sizes: 1 mg. Product ID: HY-118319. | |
| MJN228 | MJN228 is a selective ligand for the lipid-binding protein nucleobindin 1 (NUCB1) that blocks probe binding to NUCB1. It prevents AEA-DA probe labeling of NUCB1 with an IC50 value of 3.3 μM in HEK293T cell lysates. Synonyms: (4-methylpiperazin-1-yl)-(5-nitro-3-phenyl-1H-indol-2-yl)methanone. Grades: ≥98%. CAS No. 459168-97-9. Molecular formula: C20H20N4O3. Mole weight: 364.4. | |
| MK-0159 | MK-0159 is an orally active, potent and selective CD38 inhibitor, with IC50 values of 22, 3, and 70 nM for human, mouse and rat CD38, respectively. MK-0159 also shows good microsomal stability for human and rodent liver microsomes. MK-0159 increases NAD+ (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2641484-61-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-150508. | |
| MK-0249 | This active molecular is a potent histamine H3 inverse antagonist. Current antipsychotic treatments have little impact on the cognitive deficits associated with schizophrenia. MK-0249 might improve cognitive deficits in patients with schizophrenia in due to promote histamine release that may enhance cognition. In Dec 2006, Phase-II clinical trials in Alzheimer's disease in USA was on going. In Dec 2009, adverse events data from a clinical trial in healthy subjects was presented. In Jun 2012, Pharmacodynamics data from a phase I trial in Sleep apnoea syndrome was reported by Merck. Uses: Alzheimer's disease; attention-deficit hyperactivity disorder; obesity; schizophrenia; sleep apnoea syndrome. Synonyms: MK0249; MK 0249; MK-0249; 2-methyl-3-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]-5-(trifluoromethyl)quinazolin-4-one. Grades: 98%. CAS No. 1167574-41-5. Molecular formula: C23H24F3N3O2. Mole weight: 431.45. | |
| MK 0343 | MK 0343, also known as MRK-409, is a subtype-selective GABAA partial agonist (Ki values are 0.21, 0.22, 0.23 and 0.40 for α3, α1, α5 and α2 respectively). MK-0343 is a non-sedating anxiolytic in preclinical species but causes sedation in humans. Synonyms: 7-cyclobutyl-3-(2,6-difluorophenyl)-6-((1-methyl-1H-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine; MK-0343; MK 0343; MK0343; MRK 409; MRK409; MRK-409. Grades: >98%. CAS No. 233275-76-8. Molecular formula: C19H17F2N7O. Mole weight: 397.38. | |
| MK 0343 | MK 0343. Group: Biochemicals. Grades: Purified. CAS No. 233275-76-8. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| MK-0343 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| MK-0354 | MK-0354 is a partial agonist of Niacin receptor, G-protein coupled receptor 109a. Its EC50 value is 1.65/1.08 μM for hGPR109a/ mGPR109a, which show no activation of GPR109b in the cAMP assay at any concentration up to 100 μM. It demonstrated clear and statistically significant partial agonism in the cAMP assays for both the mouse and human receptors with efficacy approximately 60-70% of that of either nicotinic acid or β-hydroxy butyrate in vitro. It appeared to be somewhat unique among the members of the pyrazole tetrazole series in having reasonable receptor activity. It retained the plasma free fatty acid lowering effects in mice, but did not induce vasodilation at the maximum feasible dose in vivo. It could activate the antilipolytic pathway in adipocytes. It was developed by Arena pharmaceuticals and Merck Serono together. It had been in the two phase of clinical and been used for the treatment of atherosclerosis, but it was terminated in 2006. Uses: Mk-0354 could activate the antilipolytic pathway in adipocytes. had been used for the treatment of atherosclerosis. Synonyms: MK-0354; MK0354; MK 0354; 3-(1H-tetrazol-5-yl)-1, 4, 5, 6-tetrahydrocyclopenta[c]pyrazole;1, 4, 5, 6-Tetrahydro-3-(1H-tetrazol-5-yl)cyclopenta[c]pyrazole. Grades: >98%. CAS No. 851776-28-8. Molecular formula: C7H8N6. Mole weight: 176.18. | |
| MK-0359 | MK-0359 is a selective and potent oral PDE4 inhibitor with in vivoefficacy in animal models of asthma and cognition. Uses: Pde4 inhibitor. Synonyms: MK0359; MK 0359; MK-0359; L454560; L 454560; L-454560; 3-methyl-5-[(E)-1-(4-methylsulfonylphenyl)-2-[3-[6-(2-methylsulfonylpropan-2-yl)quinolin-8-yl]phenyl]ethenyl]-1,2,4-oxadiazole. Grades: ≥98%. CAS No. 346629-30-9. Molecular formula: C31H29N3O5S2. Mole weight: 587.15. | |
| MK-0429 | MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide pan-integrin antagonist with IC50 values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for ?v?1, ?v?3, ?v?5, ?v?6, ?v?8 and ?5?1, respectively[1][2][3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: L-000845704. CAS No. 227963-15-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-15102. | |
| MK-0429 | MK-0429 is a potent alpha(nu)beta(3) integrin inhibitor (or αvβ3 inhibitor), which showed therapeutic effects on bone turnover disease in men with hormone-refractory prostate cancer (HRPC) and bone metastases. Clinical trial results showed that MK-0429 was generally well tolerated, with the most common side-effect being nausea. There was some evidence of an early reduction of bone turnover, indicating a potential for clinical use in the treatment of bone mineral density (MBD) although serum PSA was unexpectedly increased during the study. Synonyms: L-000845704; (S)-3-(6-methoxypyridin-3-yl)-3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid; NSC776790; 3-Pyridinepropanoic acid, 6-methoxy-β-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1-imidazolidinyl]-, (βS)-. Grades: >98%. CAS No. 227963-15-7. Molecular formula: C23H29N5O4. Mole weight: 439.51. | |
| MK 0434 | MK 0434 is a Cholestenone 5-alpha reductase inhibitor originated by Merck & Co and it is associated with a significant reduction in dihydrotestosterone. No development was reported for the treatment of Alopecia, Benign prostatic hyperplasia and Prostate cancer. Uses: Alopecia, benign prostatic hyperplasia and prostate cancer. Synonyms: MK0434; MK-0434; MK 0434; MK-434; MK434; MK 434; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-7-benzoyl-4a,6a-dimethyl-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one;(5alpha,17beta)-17-Benzoyl-4-azaandrost-1-en-3-one;17beta-Benzoyl-4-aza-5alpha-androst-1-ene-3-one. Grades: 98%. CAS No. 134067-56-4. Molecular formula: C25H31NO2. Mole weight: 377.53. | |
| MK-0493 | MK-0493 is a novel, potent, and selective agonist of MC4R( melanocortin receptor 4) , which is one of the best-validated genetic targets and considered one of the most promising for the development of antiobesity therapeutics. Uses: Anti-obesity. Synonyms: MK0493; MK 0493; MK-0493; N-((S)-1-(2-(1-((3S,4R)-1-(tert-butyl)-4-(2,4-difluorophenyl)pyrrolidine-3-carbonyl)piperidin-4-yl)-5-chlorophenyl)ethyl)acetamide hydrochloride. Grades: ≥98%. CAS No. 455957-71-8. Molecular formula: C30H39Cl2F2N3O2. Mole weight: 582.55. | |
| MK-0493 | MK-0493 is a potent, orally active and selective agonist of the melanocortin receptor 4 (MC4R) , demonstrating significant reductions in energy intake [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 455956-93-1. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-118930. | |
| MK-0493 Free base | MK-0493 is a novel, potent, and selective agonist of the melanocortin receptor 4 (MC4R), one of the best-validated genetic targets and considered one of the most promising for the development of antiobesity therapeutics. Uses: Undefined mechanism. Synonyms: MK0493; MK 0493; MK-0493; N-((S)-1-(2-(1-((3S,4R)-1-(tert-butyl)-4-(2,4-difluorophenyl)pyrrolidine-3-carbonyl)piperidin-4-yl)-5-chlorophenyl)ethyl)acetamide. Grades: ≥98%. CAS No. 455956-93-1. Molecular formula: C30H38ClF2N3O2. Mole weight: 546.09. | |
| MK-0493 hydrochloride | MK-0493 hydrochloride is a potent, orally active and selective agonist of the melanocortin receptor 4 (MC4R) , demonstrating significant reductions in energy intake [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 455957-71-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg. Product ID: HY-118930A. | |
| MK 0524 sodium salt | MK 0524 sodium salt is a potent and selective prostaglandin D2 (PGD2) receptor 1 (DP1) antagonist with Ki values to be 0.57 nM and 750 nM for DP1 and DP2 receptors, respectively. Synonyms: MK 0524 sodium salt; MK0524 sodium salt; MK-0524 sodium salt; Laropiprant sodium; 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid sodium. Grades: 99%. CAS No. 572874-50-1. Molecular formula: C21H18ClFNNaO4S. Mole weight: 457.88. | |
| MK0533 | MK0533 is a novel selective peroxisome proliferator-activated receptor gamma modulator. It is used for the treatment of type 2 diabetes mellitus. It reduces potential to increase plasma and extracellular fluid volume. It showed diminished maximal activity in cell-based transcription activation assays and attenuated gene signatures in adipose tissue. Uses: Mk0533 is used for the treatment of type 2 diabetes mellitus. Synonyms: MK-0533; MK 0533; (R)-2-(3-(3-(4-methoxybenzoyl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl)phenoxy)butanoic acid. Grades: 98%. CAS No. 668455-28-5. Molecular formula: C28H24F3NO6. Mole weight: 527.50. | |
| MK 0557 | MK-0557 is a highly selective, orally administered neuropeptide NPY5R antagonist, could limit weight regain after very-low-calorie diet (VLCD)-induced weight loss. Uses: Npy5r antagonist. Synonyms: MK0557; MK 0557; MK-0557; N-[1-(2-fluorophenyl)pyrazol-3-yl]-1'-oxospiro[cyclohexane-4,3'-furo[3,4-c]pyridine]-1-carboxamide. Grades: ≥98%. CAS No. 328232-95-7. Molecular formula: C22H19FN4O3. Mole weight: 406.41. | |
| MK-0591 | Quiflapon is a synthetic compound which specifically inhibits the activity of 5-Lox and is currently under development for the treatment of asthma. Also, Quiflapon, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells. Synonyms: Quiflapon; MK 591; MK-591; MK591; L 686708; L-686708; L686708; L-686,708; L 686,708; L686,708. Grades: >98%. CAS No. 136668-42-3. Molecular formula: C34H35ClN2O3S. Mole weight: 587.17. | |
| MK-0634 | MK-0634, also called as L-796568, is an β3 adrenergic receptor agonist that was progressed into clinical studies for the treatment of obesity in the early 2000s but discontinued due to unacceptable toxicity. Synonyms: MK-0634; MK 0634; MK0634; N-[4-[2-[[(2R)-2-hydroxy-2-pyridin-3-ylethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]benzenesulfonamide; 2-hydroxy-PEAPTTB; L-796568 free base; L 796568 free base; L796568 free base; 211031-81-1 (L-796568 dihydrochloride); N-(4-(2-((2-hydroxy-2-(3-pyridinyl)ethyl)amino)ethyl)phenyl)-4-(4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)benzenesulfonamide. Grades: >98%. CAS No. 211031-01-5. Molecular formula: C31H27F3N4O3S2. Mole weight: 624.697. | |
| MK-0634 dihydrochloride | MK-0634, also called as L-796568, is an β3 adrenergic receptor agonist that was progressed into clinical studies for the treatment of obesity in the early 2000s but discontinued due to unacceptable toxicity. Uses: Adrenergic beta-3 receptor agonists. Synonyms: N-[4-[2-[[(2R)-2-hydroxy-2-pyridin-3-ylethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]-1, 3-thiazol-2-yl]benzenesulfonamide; dihydrochloride; L-796568 dihydrochloride; 211031-81-1 (L-796568 dihydrochloride); 211031-01-5 (L-796568 Free base); MK 0634 dihydrochloride; MK0634 dihydrochloride; MK-0634 dihydrochloride; L-796568 dihydrochloride; L 796568 dihydrochloride; L796568 dihydrochloride. Grades: >98%. CAS No. 211031-81-1. Molecular formula: C31H29Cl2F3N4O3S2. Mole weight: 697.61. | |
| MK-0668 | MK-0668 is an antagonist of very late antigen-4 with picomolar, whole blood activity and slow dissociation rates were discovered by incorporating an amino substituent on the proline fragment of the initial lead structure. Synonyms: MK0668; MK 0668; MK-0668; (S) -2- ( (2S, 4R) -1- ( (3-cyanophenyl) sulfonyl) -4- (cyclobutylamino) pyrrolidine-2-carboxamido) -3- (4- (3, 5-dichloroisonicotinamido) phenyl) propanoic acid. Grades: 98%. CAS No. 865110-07-2. Molecular formula: C31H30Cl2N6O6S. Mole weight: 685.59. | |
| MK-0668 mesylate | MK-0668 is an antagonist of very late antigen-4 with picomolar, whole blood activity and slow dissociation rates were discovered by incorporating an amino substituent on the proline fragment of the initial lead structure. Synonyms: MK0668; MK 0668; MK-0668; (S) -2- ( (2S, 4R) -1- ( (3-cyanophenyl) sulfonyl) -4- (cyclobutylamino) pyrrolidine-2-carboxamido) -3- (4- (3, 5-dichloroisonicotinamido) phenyl) propanoic acid mesylate. Grades: 98%. CAS No. 865111-04-2. Molecular formula: C31H30Cl2N6O6S.CH4O3S. Mole weight: 781.69. | |
| MK 0677 | MK 0677. Group: Biochemicals. Grades: Purified. CAS No. 159752-10-0. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| MK0686 | MK0686 is a bradykinin B1 receptor antagonist. It exhibits suitable pharmacokinetic properties and efficient ex vivo receptor occupancy for further development as a novel approach for the treatment of pain and inflammation. It had been in phase II clinical trials by Merck Sharp & Dohme for the treatment of postherpetic neuralgia, postoperative pain and osteoarthritis. But it is discontinued now. Uses: Mk0686 is used for the treatment of postherpetic neuralgia, postoperative pain and osteoarthritis. Synonyms: MK0686; MK 0686; MK-0686;Methyl 2-chloro-6- [3-fluoro-4- [ (1R) -1- [ [1- [ (2, 2, 2-trifluoroacetyl) amino] cyclopropanecarbonyl] amino] ethyl] phenyl] benzoate; Methyl (R)-3-chloro-3'-fluoro-4'-(1-(1-(2,2,2-trifluoroacetamido)cyclopropane-1-carboxamido)ethyl)-[1,1'-biphenyl]-2-carboxyla. Grades: 98%. CAS No. 578727-68-1. Molecular formula: C22H19ClF4N2O4. Mole weight: 486.85. | |
| MK-0731 | MK-0731 is a selective, non-competitive and allosteric kinesin spindle protein (KSP) inhibitor with an IC50 of 2.2 nM and a pKa of 7.6. MK-0731 is >20,000 fold selectivity against other kinesins. MK-0731 induces mitotic arrest and induces apoptosis in tumors. MK-0731 provides significant antitumor efficacy[1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 845256-65-7. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-50672. | |
| MK-0731 | MK-0731 is a synthetic small molecule with potential antineoplastic activity. MK0731 selectively inhibits kinesin spindle protein (KSP), which may result in the inhibition of mitotic spindle assembly, induction of cell cycle arrest during the mitotic phase, and apoptosis in tumor cells that overexpress KSP. Uses: Potential antineoplastic agent. Synonyms: ALR-3456; ALR 3456; ALR3456; 845256-65-7; MK0731, MK-0731, MK 0731; UNII-8HIJ5G3O02; 8HIJ5G3O02. CAS No. 845256-65-7. Molecular formula: C25H28F3N3O2. Mole weight: 459.513. | |
| Mk-0752 | Mk-0752. Uses: Designed for use in research and industrial production. Additional or Alternative Names: MK-0752, 471905-41-6, MK 0752, 471905-41-6, MK0752, MK 0752, 3-((1r,4s)-4-(4-chlorophenylsulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid, cc-14, SureCN756247, SureCN756248, SureCN756249, MK0752, RW3012, BCP9000935, BCP9000936, CS-0253, QC-1905, RL03744, NCGC00263184-01, HY-10974, X7591, L-000891675. Product Category: Heterocyclic Organic Compound. CAS No. 952578-68-6. Molecular formula: C21H21ClF2O4S. Mole weight: 442.903846 [g/mol]. Purity: 0.96. IUPACName: 3-[4-(4-chlorophenyl)sulfonyl-4-(2,5-difluorophenyl)cyclohexyl]propanoic acid. Canonical SMILES: C1CC(CCC1CCC(=O)O)(C2=C(C=CC(=C2)F)F)S(=O)(=O)C3=CC=C(C=C3)Cl. Density: 1.361±0.06 g/cm³ (20 °C, 760 mmHg). Product ID: ACM952578686. Alfa Chemistry ISO 9001:2015 Certified. | |
| MK-0752 | MK-0752 is a gamma secretase inhibitor in clinical development. Group: Biochemicals. Alternative Names: cis-4-[ (4-Chlorophenyl) sulfonyl]-4- (2, 5-difluorophenyl) cyclohexanepropanoic Acid. Grades: Highly Purified. CAS No. 471905-41-6. Pack Sizes: 5mg. US Biological Life Sciences. | Worldwide |
| MK-0752 | MK-0752 is a potent, orally active and specific ?-secretase inhibitor, showing dose-dependent reduction of A?40 with an IC50 of 5 nM in human SH-SY5Y cells. MK-0752 crosses the blood-brain barrier. MK-0752 reduces newly generated CNS A? in vivo[1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 471905-41-6. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10974. | |
| MK-0752 | MK 0752 is a potent and reversible inhibitor of γ-secretase (IC50 ~50 nM). It was shown to reduce the number of breast cancer stem cells in tumorgrafts. Uses: Gamma secretase inhibitors and modulators. Synonyms: Cyclohexanepropanoic acid, 4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)-, cis-; cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid; MK 0752; MK0752. Grades: >98%. CAS No. 471905-41-6. Molecular formula: C21H21ClF2O4S. Mole weight: 442.91. | |
| MK-0752 sodium salt | MK-0752 sodium salt is a novel potent γ-secretase inhibitor. It is in clinical trial for treatment of several types of cancer. Uses: Mk-0752 sodium salt is used for treatment of several types of cancer. Synonyms: MK0752; MK 0752; MK-0752; MK0752 sodium salt;Sodium 3-(4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoate. Grades: 98%. CAS No. 656810-87-6. Molecular formula: C21H20ClF2NaO4S. Mole weight: 464.88. | |
| MK 0812 | MK 0812. Group: Biochemicals. Grades: Highly Purified. CAS No. 624733-88-6. Pack Sizes: 50mg, 100mg, 250mg, 500mg, 1g. US Biological Life Sciences. | Worldwide |
| MK-0812 | MK-0812 is a potent and selective CCR2 antagonist with low affinity for CCR2 on human monocytes. Synonyms: MK-0812; MK 0812; MK0812; [(1S,3R)-3-[[(3S,4S)-3-methoxyoxan-4-yl]amino]-1-propan-2-ylcyclopentyl]-[3-(trifluoromethyl)-7,8-dihydro-5H-1,6-naphthyridin-6-yl]methanone. CAS No. 624733-88-6. Molecular formula: C24H34F3N3O3. Mole weight: 469.54. | |
| MK-0822 | MK-0822 is a newly developed bone-targeting dual action pro-drug for osteoporosis and bone metastasis. It is also an inhibitor of cathepsin K, an enzyme involved in bone resorption. Group: Biochemicals. Alternative Names: N- (1-cyanocyclopropyl) -4-fluoro-N2-{ (1S) -2, 2, 2-trifluoro-1-[4'- (methylsulfonyl) biphenyl-4-yl]ethyl}-L-leucinamide, Odanacatib. Grades: Highly Purified. CAS No. 603139-19-1. Pack Sizes: 5mg. US Biological Life Sciences. | Worldwide |
| MK0873 | MK0873 is a phosphodiesterase 4 (PDE4) inhibitor. It has shown as an innovative tool to design topical formulation to achieve desired pharmacokinetics in humans along with a minipig skin biopsy model. It was developed by Merck. It was used to treat rheumatoid arthritis in phase II clinical trials and plaque psoriasis in phase I clinical trials, but it has no recent research progress. Uses: Mk0873 was used to treat rheumatoid arthritis and plaque psoriasis. Synonyms: N-cyclopropyl-1-[3-[2-(1-oxidopyridin-1-ium-3-yl)ethynyl]phenyl]-4-oxo-1,8-naphthyridine-3-carboxamide;MK0873; MK 0873; MK-0873;3-((3-(3-(cyclopropylcarbamoyl)-4-oxo-1,8-naphthyridin-1(4H)-yl)phenyl)ethynyl)pyridine 1-oxide. Grades: 98%. CAS No. 500355-52-2. Molecular formula: C25H18N4O3. Mole weight: 422.44. | |
| MK 0893 | MK-0893 is a potent, selective glucagon receptor antagonist with high binding affinity with IC(50) of 6.6 nM and functional cAMP activity with IC(50) of 15.7 nM. It is selective for glucagon receptor relative to other family B GPCRs and is > 200 fold selectivity for GIPR, PAC1, GLP-1R, VPAC1 and VPAC2. It blunted glucagon-induced glucose elevation in hGCGR mice and rhesus monkeys. It may be a potential oral treatment for type 2 diabetes. It was selected for further preclinical and clinical evaluations. Uses: Mk-0893 may be a potential oral treatment for type 2 diabetes. Synonyms: MK 0893; MK0893; MK-0893; b-Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]-;Merk Glucagon antagonist;N-[4-[(1S)-1-[3-(3,5-Dichlorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]-beta-alanine;(S)-3-(4-(1-(3-(3,5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl)ethyl)benzamido)propanoic acid. Grades: >98 %. CAS No. 870823-12-4. Molecular formula: C32H27Cl2N3O4. Mole weight: 588.48. | |
| MK 0893 | MK 0893 is a potent and selective glucagon receptor antagonist with an IC50 of 6.6 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 870823-12-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-50663. | |
| MK0916 | MK0916 is an 11β-hydroxysteroid dehydrogenase type 1 inhibitor. It is used for patients with type 2 diabetes mellitus and metabolic syndrome and obesity-related disorders. It produces mechanism-based activation of the hypothalamic-pituitary-adrenal axis and results in mean increases in adrenal androgen levels that remains within the normal range. Uses: Mk0916 is used for patients with type 2 diabetes mellitus and metabolic syndrome and obesity-related disorders. Synonyms: MK 0916; MK-0916; 3-((1s,3s)-1-(4-chlorophenyl)-3-fluorocyclobutyl)-4,5-dicyclopropyl-4H-1,2,4-triazole. Grades: 98%. CAS No. 633317-53-0. Molecular formula: C18H19ClFN3. Mole weight: 331.82. | |
| MK 0927 | MK 0927 is a potential bio-active agent., but no detail information has been published yet. Synonyms: MK0927; MK-0927; MK 0927; 4-(2-methylpropylamino)-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide;hydrochloride. Grades: 98%. CAS No. 126453-94-9. Molecular formula: C11H19ClN2O4S3. Mole weight: 374.91. | |
| MK-0941 mesylate | MK-0941 is a glucokinase activator used for the treatment of type II diabetes. It increases the risk of hypoglycemia and elevations in triglycerides and blood pressure. Synonyms: MK-0941; MK 0941; MK0941; 3-(6-ethylsulfonylpyridin-3-yl)oxy-5-[(2S)-1-hydroxypropan-2-yl]oxy-N-(1-methylpyrazol-3-yl)benzamide mesylate. Grades: ≥98%. CAS No. 1137916-97-2. Molecular formula: C21H24N4O6S·CH3SO3H. Mole weight: 556.61. | |
| MK-0969 | MK-0969 is an Muscarinic M3 antagonist which has the potential for the treatment of chronic obstructive pulmonary diseases. Synonyms: (2R)-N-[1-[(6-aminopyridin-2-yl)methyl]piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide; MK0969; MK 0969; MK-0969; J-104135; J 104135; J104135. Grades: >98%. CAS No. 203321-88-4. Molecular formula: C24H30F2N4O2. Mole weight: 444.53. | |
| Mk1064 | Mk1064 is a selective orexin OX2 receptor antagonist for potential treatment of insomnia. Studies shows that Mk1064 could promote sleep and increase both rapid eye movement (REM) and non-REM (NREM) sleep of humans. Uses: Mk1064 is a selective orexin ox2 receptor antagonist. Synonyms: MK1064; MK 1064; MK-1064; 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide. Grades: ≥98%. CAS No. 1207253-08-4. Molecular formula: C24H20ClN5O3. Mole weight: 461.91. | |
| MK-1084 | MK-1084 is a selective KRAS G12C inhibitor that is currently in Phase I clinical trial (NCT05067283). MK-1084 exhibits anticancer activity and can be used either alone or in combination with pembrolizumab (HY-P9902) for cancer research [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2641216-67-1. Pack Sizes: 1 mg; 5 mg. Product ID: HY-162431. | |
| MK-142 dimethanesulfonate | MK-142 is a bioactive agent with antiarrhythmic properties with its content in the skeletal muscles indicates a high affinity of the examined substance to the heart muscle. Uses: Antiarrhytmic. Synonyms: MK142; MK-142; MK 142; 3,3'-(ethane-1,2-diylbis(azanediyl))bis(1-(4-methoxyphenoxy)propan-2-ol). Grades: ≥95%. CAS No. 42794-63-8. Molecular formula: C22H32N2O6. Mole weight: 420.50. | |
| MK-1775 | MK-1775, also known as AZD-1775, is a WEE1 inhibitor and a small-molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. MK-1775 selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. Unlike normal cells, most p53-deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53-deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect. Synonyms: MK-1775; MK1775; MK 1775; AZD1775; AZD-1775; AZD 1775; adavosertib. 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one. Grades: >98%. CAS No. 955365-80-7. Molecular formula: C27H32N8O2. Mole weight: 500.607. | |
| MK190 | MK190 is a synthetic bio-active chemical. Uses: A synthetic bio-active chemical. Synonyms: MK190; MK-190; MK 190; 2-(4-fluorophenyl)-1-methyl-5-nitro-1H-imidazole. Grades: ≥98%. CAS No. 4204-99-3. Molecular formula: C10H8FN3O2. Mole weight: 221.19. | |
| MK 1903 | MK 1903 is a hydroxycarboxylic acid receptor 2 (GPR109A) agonist. It may be used in the treatment of obesity and related weight disorders. Synonyms: MK 1903; MK1903; MK-1903; (4aR, 5aR)-4, 4a, 5, 5a-Tetrahydro-1H-cyclopropa[4, 5]cyclopenta[1, 2]pyrazole-3-carboxylic acid. Grades: ≥98% by HPLC. CAS No. 1268882-43-4. Molecular formula: C8H8N2O2. Mole weight: 164.16. | |
| MK 1903 | MK 1903. Group: Biochemicals. Grades: Purified. CAS No. 1268882-43-4. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| MK 1-907 | MK-1-907 is a centrally acting drug, but no detailed information has been published yet. Uses: Centrally acting drug. Synonyms: MK1907; MK-1-907; MK-1907; MK1-907; MK-1-907; 3- ( (3-methoxyphenyl)amino)-5, 5-dimethyl-2- ( (methyl (phenethyl)amino)methyl)cyclohex-2-en-1-one. Grades: 98%. CAS No. 78150-06-8. Molecular formula: C25H32N2O2. Mole weight: 392.54. | |
| MK204 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| MK-2048 | MK-2048 is a second generation integrase inhibitor (IC50=2.6 nM). It can inhibits the HIV enzyme integrase 4 times longer than raltegravir. Synonyms: MK2048; MK 2048; MK-2048. Grades: >98%. CAS No. 869901-69-9. Molecular formula: C22H24FN5O4. Mole weight: 441.46. | |
| MK-2048 | MK-2048 represents a prototype second generation integrase strand transfer inhibitor (INSTI), it was developed with the goal of retaining activity against viruses containing mutations assiciated with resistance of first-generation INSTIs, raltegravir. MK-2048 exhibits inhibitory activity towards HIV integrase and towards HIV replication. It is four times more effective in inhibiting HIV enzyme integrase than the first generation inhibitor, raltegravir. Group: Biochemicals. Alternative Names: (6S)-2-(3-Chloro-4-fluorobenzyl)-8-ethyl-10-hydroxy-N, 6-dimethyl-1, 9-dioxo-1, 2, 6, 7, 8, 9-hexahydropyrazino[1', 2':1, 5]pyrrolo[2, 3-d]pyridazine-4-carboxamide. Grades: Highly Purified. CAS No. 869901-69-9. Pack Sizes: 5mg. US Biological Life Sciences. | Worldwide |
| MK212 | MK212 is a 5HT2C-receptor agonist. It exhibited anxiolytic activity in mice at low doses. It is a serotonin agonist. It could promote the secretion of serum prolactin and cortisol in humans. Uses: Mk212 exhibites anxiolytic activity and could promote the secretion of serum prolactin and cortisol in humans. Synonyms: MK212; MK 212; MK-212; 2-Chloro-6-(1-piperazinyl)pyrazine;MK-212;2-Chloro-6-(piperazin-1-yl)pyrazine. Grades: 98%. CAS No. 64022-27-1. Molecular formula: C8H11ClN4. Mole weight: 198.65. | |
| MK 212 hydrochloride | MK 212 hydrochloride. Group: Biochemicals. Grades: Purified. CAS No. 61655-58-1. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| MK-212 hydrochloride | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| MK212 hydrochloride | MK212 hydrochloride is a selective 5-HT2C serotonin receptor agonist. It displays selectivity for 5-HT2C over 5-HT2A with IC50 values of 0.028 and 0.42 μM for human 5-HT2C and 5-HT2A receptors expressed in HEK293 cells respectively. Uses: Serotonin receptor agonists. Synonyms: MK212; MK 212; MK-212; MK-212 hydrochloride;1-(6-Chloro-2-pyrazinyl)piperazine monohydrochloride;2-Chloro-6-(1-piperazinyl)pyrazine monohydrochloride. Grades: 98%. CAS No. 61655-58-1. Molecular formula: C8H12Cl2N4. Mole weight: 235.11. | |
| MK-2206 | MK-2206 Inhibitor. Uses: Scientific use. Product Category: T1952. CAS No. 1032350-13-2. |  |
| MK-2206 | MK-2206 is an allosteric inhibitor of Akt that prevents translocation of Akt to membranes. It is also an orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B). It binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. It has potential antineoplastic activity. It exhibits anticancer chemotherapeutic activity in a variety of in vitro cancer models. It induces G1-phase cell cycle arrest in hepatocellular carcinoma cells, inhibits cell proliferation in non-small cell lung cancer cells, and inhibits proliferation in medullary thyroid cancer cells. It also inhibits tumor growth in animal models of nasopharyngeal cancer. It was developed by Merck Sharp & Dohme and in clinic phase 2 trials. Uses: Mk-2206 has potential antineoplastic activity. Synonyms: MK2206; MK 2206; MK-2206; 8-(4-(1-Aminocyclobutyl)phenyl)-9-phenyl-8,9-dihydro-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one;8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one. Grades: 95%. CAS No. 1032349-93-1. Molecular formula: C25H21N5O. Mole weight: 407.47. | |
Our database is helping our users find suppliers everyday.
